Why is Eli Lilly acquiring 4E Therapeutics for non‑opioid pain research?

Eli Lilly is buying 4E Therapeutics to strengthen its non‑opioid, non‑addictive pain portfolio and rebuild its pain franchise after recent setbacks. The acquisition adds 4E’s MNK inhibitor programs, including 4ET1103 for nerve‑damage pain, aligning with Lilly’s strategy to reinvest obesity‑drug gains into early‑stage, diversified pain therapies.